Abbott Laboratories (ABT) Monday announced that the U.S. Food and Drug Administration has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System for patients suffering from chronic limb-threatening ischemia below-the-knee or CLTI-BTK.
CLTI is a form of peripheral artery disease, where clogged arteries disrupt the supply of blood and oxygen in the lower leg and foot.
The company stated that the innovative stent is implanted in the leg through a minimally invasive procedure to open the blockages. Following this, the device supports the vessels for around three years until the vessels become stronger.
Currently, Abbott's stock is trading at $107.75, up 0.20 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.